Pronounced reduction of postprandial glucagon by lixisenatide:a meta-analysis of randomized clinical trials

Ahrén, B., Gautier, J.-F., Berria, R., Stager, W., Aronson, R. and Bailey, C.J. (2014). Pronounced reduction of postprandial glucagon by lixisenatide:a meta-analysis of randomized clinical trials. Diabetes, Obesity and Metabolism, 16 (9), pp. 861-868.


Glucagon-like peptide-1 (GLP-1) receptor agonists improve islet function and delay gastric emptying in patients with type 2 diabetes mellitus (T2DM). This meta-analysis aimed to investigate the effects of the once-daily prandial GLP-1 receptor agonist lixisenatide on postprandial plasma glucose (PPG), glucagon and insulin levels. Methods: Six randomized, placebo-controlled studies of lixisenatide 20μg once daily were included in this analysis: lixisenatide as monotherapy (GetGoal-Mono), as add-on to oral antidiabetic drugs (OADs; GetGoal-M, GetGoal-S) or in combination with basal insulin (GetGoal-L, GetGoal-Duo-1 and GetGoal-L-Asia). Change in 2-h PPG and glucose excursion were evaluated across six studies. Change in 2-h glucagon and postprandial insulin were evaluated across two studies. A meta-analysis was performed on least square (LS) mean estimates obtained from analysis of covariance (ANCOVA)-based linear regression. Results: Lixisenatide significantly reduced 2-h PPG from baseline (LS mean difference vs. placebo: -4.9mmol/l, p<0.001) and glucose excursion (LS mean difference vs. placebo: -4.5mmol/l, p<0.001). As measured in two studies, lixisenatide also reduced postprandial glucagon (LS mean difference vs. placebo: -19.0ng/l, p<0.001) and insulin (LS mean difference vs. placebo: -64.8 pmol/l, p<0.001). There was a stronger correlation between 2-h postprandial glucagon and 2-h PPG with lixisenatide than with placebo. Conclusions: Lixisenatide significantly reduced 2-h PPG and glucose excursion together with a marked reduction in postprandial glucagon and insulin; thus, lixisenatide appears to have biological effects on blood glucose that are independent of increased insulin secretion. These effects may be, in part, attributed to reduced glucagon secretion. © 2014 John Wiley and Sons Ltd.

Publication DOI:
Divisions: Life & Health Sciences > Biosciences
Life & Health Sciences
Life & Health Sciences > Applied Health Research Group
Life & Health Sciences > Biomedical Sciences research group
Additional Information: Presented at the 73rd Annual Meeting of the American Diabetes Association, 21–25 June 2013, Chicago, IL, USA; 49th Annual Meeting of the European Association for the Study of Diabetes, 23–27 September 2013, Barcelona, Spain.
Uncontrolled Keywords: diabetes mellitus,GLP-1,insulin secretion,Internal Medicine,Endocrinology,Endocrinology, Diabetes and Metabolism
Full Text Link:
Related URLs:
Published Date: 2014-09
Authors: Ahrén, B.
Gautier, J.-F.
Berria, R.
Stager, W.
Aronson, R.
Bailey, C.J. ( 0000-0002-6998-6811)


Item under embargo

Export / Share Citation


Additional statistics for this record